Youdim Pharmaceuticals

Youdim Pharmaceuticals is a biopharmaceutical company focused on the development of multi-target directed ligands (MTDLs) for the treatment of neurodegenerative disorders, including Parkinson's and Alzheimer's diseases. Founded by Professor Moussa Youdim, a pioneer in the development of Rasagiline (Azilect), the company leverages his expertise in monoamine oxidase (MAO) inhibition and iron chelation. Their therapeutic approach involves creating bifunctional small molecules that combine neuroprotective iron-chelating properties with enzyme inhibition to address the complex, multifactorial nature of brain aging and neurodegeneration. The company's pipeline primarily consists of optimized derivatives of rasagiline and other novel scaffolds designed to cross the blood-brain barrier and provide disease-modifying effects.